Skip to main content
Clinical Trials/NL-OMON43495
NL-OMON43495
Completed
N/A

Markers for neurocognitive impairment in congenitally CMV infected infants: MARVELYS study - MARVELYS study

Academisch Medisch Centrum0 sites100 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
congenital cytomegalovirus infection
Sponsor
Academisch Medisch Centrum
Enrollment
100
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • Positive Polymerase Chain Reaction (PCR) detection of the CMV in urine or blood in neonates younger than 10 days of life and/or positive CMV PCR in dried blood spot (Guthriecard) in children older than 10 days of age
  • Age: birth \- three months of age
  • Written informed consent from the parent(s) or guardian(s).

Exclusion Criteria

  • No signed consent from the parent(s) or guardian(s).
  • MRI contra\-indications (e.g. implanted active devices such as pacemakers or medication pumps)

Outcomes

Primary Outcomes

Not specified

Similar Trials